Agenda
Applications for consideration at this meeting
- 1495 Somatic tumour gene panel test
- 1512 Apolipoprotein B testing for high risk cardiovascular disease risk assessment
- 1518 Endoscopic non-contact (side-firing) visual laser ablation of the prostate (VLAP) for benign prostatic hyperplasia (BPH)
- 1519 Tisagenlecleucel (CTL019) for treatment of refractory CD19-positive leukaemia and lymphoma
- 1522 PD-L1 (Programmed Death-Ligand 1) immunohistochemistry testing for access to pembrolizumab as first-line therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma (co-dependent)
- 1524 Expanding the BRAF testing MBS item to include patients with resectable Stage III melanoma (co-dependent)
- 1525 Low dose rate (LDR) brachytherapy for intermediate and high-risk prostate cancer
- 1526 Somatic tumour gene testing for the diagnosis of diffuse large B cell lymphoma, multiple myeloma and non-Hodgkin lymphoma subtypes
- 1527 Somatic tumour gene testing for the diagnosis of gliomas, gliobastomas, and soft tissue and bone tumours
- 1528 Somatic tumour gene testing for the diagnosis of renal cell carcinoma, hydatidiform moles, granulosa cell ovarian tumour, salivary gland tumours, and secretory carcinoma of the breast
- 1530 Purified human alpha1-proteinase inhibitor (A1-PI) for the treatment of alpha1-proteinase inhibitor deficiency, leading to chronic obstructive pulmonary disease (COPD)
Related information
Committee: